Trial intelligence / Profile preview

Nivolumab plus ipilimumab versus nivolumab plus ipilimumab placebo in recurrent or metastatic SCCHN

2016-001645-64Phase 2Completed

Sponsor: Bristol Myers Squibb
Start: Aug 2016
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) and squamous cell carcinoma (SCC) comparing Nivolumab + ipilimumab with Nivolumab + ipilimumab placebo (2 arms). Primary endpoint: Overall response rate in platinum refractory subgroup. Started Aug 2016; status: completed.

Drugs

nivolumabipilimumab

Conditions

head and neck squamous cell carcinoma (HNSCC)squamous cell carcinoma (SCC)

Beyond the preview

Go deeper on 2016-001645-64.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2016-001645-64.